High-risk content policy
Content categories that Peptide Authority will not publish, and content categories that trigger an extra editorial review step before publication.
Last reviewed:
Content we will not publish
The following content categories are off-limits across every page on Peptide Authority and across every channel where Peptide Authority is published (site, newsletter, social, forum). These limits are permanent and apply regardless of editorial argument, commercial opportunity, or reader demand.
- Dosing instructions for unlicensed compounds. We do not publish microgram values, dose-response tables, escalation schedules, or “starter” doses for any peptide that is not a licensed UK medicine. For licensed medicines we direct readers to the SmPC and their prescriber, not to a Peptide Authority figure. See no dosing, no sourcing.
- Reconstitution recipes for unlicensed compounds. We do not publish bacteriostatic-water volume calculations, syringe-marking guides, or step-by-step reconstitution.
- Injection technique for unlicensed compounds. We do not publish needle gauge, injection site, rotation schedule, or technique guidance.
- Supplier rankings, “best place to buy”, “trusted vendor” lists. We do not rank, recommend, score, or tier-list unregulated suppliers. The closest we come is the single, openly-disclosed Peptide Barn affiliate link covered in the affiliate disclosure policy.
- Sourcing instructions for compounded GLP-1. We do not publish step-by-step guides on accessing “compounded semaglutide” or other GLP-1 supply outside the regulated UK framework.
- Athlete dose protocols or detection-window guidance. We do not publish protocols designed to maximise performance gain before testing or to evade detection.
- Stack-building instructions for unlicensed compounds. We publish evidence reviews of commonly-marketed combinations (e.g. BPC-157 + TB-500) at /stacks/claim-reviews; we do not publish “how to run” instructions.
- Personal medical advice. We do not answer reader questions of the form “should I take this?”, “how much should I take?”, or “is my supplier legit?”. We direct readers to a GMC-registered clinician.
Content that triggers extra review
Some categories are publishable but trigger an additional reviewer check before release:
- Pages mentioning paediatric use, pregnancy, breastfeeding, or fertility.
- Pages mentioning interactions between peptides and any prescription medicine class (anticoagulants, insulin, SSRIs, immunosuppressants, etc.).
- Pages with mental-health relevance (suicide, self-harm, eating disorders) — we add NHS crisis numbers and Samaritans contact regardless of topic.
- Pages mentioning specific brand names of UK-licensed medicines (Wegovy, Mounjaro, Ozempic, Saxenda, etc.) — checked against the SmPC and current NICE TA position.
- Pages with regulatory enforcement content — checked against the MHRA original alert text before publication.
User-generated content
The forum / community at /community is moderated against the same high-risk-content rules. Posts that request, share, or imply dosing instructions, supplier sources, reconstitution methods, or sourcing-evasion advice are removed and the poster is warned. The forum-specific framework lives at /community/safety-policy and /community/moderation-policy.
Reporting a breach
If a page on the site appears to cross any of these lines, please send the URL to us via the corrections process. High-risk-content failures are treated as urgent.